Larry Biegelsen
Recent Quotes
"An investment in the long-term future for INO is a solid investment choice."
—
Biotech Research Group, Seeking Alpha
(6/21/16)
more >
"We expect JNJ's drug pipeline to deliver accelerating growth."
—
Larry Biegelsen, Wells Fargo & Co.
(3/1/13)
more >
"We expect upcoming catalysts to drive strong EW's Sapien sales growth."
—
Larry Biegelsen, Wells Fargo & Co.
(1/28/13)
more >
"We expect JNJ's pipeline to deliver accelerating growth."
—
Larry Biegelsen, Wells Fargo & Co.
(1/8/13)
more >
"JNJ's Xarelto still has the most indications among the three new anticoagulants."
—
Larry Biegelsen, Wells Fargo & Co.
(12/31/12)
more >
"JNJ's Xarelto should capture the lion's share of the U.S. market."
—
Larry Biegelsen, Wells Fargo & Co.
(11/2/12)
more >
"GARY showed favorable mortality rates with TAVI using EW's Sapien."
—
Larry Biegelsen, Wells Fargo & Co.
(8/27/12)
more >
"MDT's Ardian represents a compelling, long term opportunity."
—
Larry Biegelsen, Wells Fargo & Co.
(8/23/12)
more >
